Cardiac muscle regeneration using mesenchymal stem cells
AssigneeOsiris Therapeutics, Inc.
InventorsMark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
Claims7
A method of improving ventricular wall motion of the heart of an individual, comprising:
- administering to said individual autologous or allogeneic mesenchymal stem cells, wherein said mesenchymal stem cells are administered in an amount effective to improve ventricular wall motion of the heart of said individual.
Dependencies are inferred from the claim text.